BUILDING SAFER AND MORE POTENT TREATMENTS
OUR SOLUTION
Deliver safer and more potent ADCs Targeting Surface Protein Complexes
DISCOVERY
As reported by Centrose in Nature Communications, a cell’s Surfaceome is a collection of distinct interacting proteins that allow the cell to function and communicate with other cell types. Importantly, these networks are cell type specific and thus can be targeted with precision medicines.
EDCs are True Next-Gen ADCs
EDCs are antibody drug conjugates (ADCs) that don’t require internalization, nor do they require breakdown. In fact, for EDCs to work, the drug has to be attached to the antibody and the two target proteins have to be outside of the cell. This is why we named them Extracellular Drug Conjugates or EDCs, a true Next-Gen ADC platform.
Benefits of Extracellular Targeting
Centrose discovered that certain proteins form communities on the surface of diseased cells and these communities are disease specific. Centrose then went on to discover EDCs, a new type of ADC that selectively kills cancer cells when both the antibody and drug bind their targets when they are in close proximity, within a community. Centrose went on to discover that the EDC drug target was expressed on many diseased cell types but found in specific communities. This meant that by changing the antibody, Centrose could selectively target different diseases with a single drug using EDCs. Since, EDCs have now been shown to be potent and safe in non-human primate models at efficacious dosing. So now there is a new type of ADC that encompasses an entirely new set of targets, including non-internalizing targets, that can be used to make selective drugs with the potency and safety of the ADC.
As we reported in cell press publication, Centrose provides data showing that proteins like CD20 and CD38 also are involved in cell surface communities. With this knowledge, Centrose has since developed a number of EDCs for different cancer types like lung, pancreatic and lymphomas.
PIPELINE
EDC9 targets drug resistant NHL.
EDC1 targets metastatic cancers.
EDC8 targets certain types of lymphoma.
